Search Within

Owen O'connor

Formats
  1. Meeting Abstract (55)
  2. Journal Article (42)
  3. Book Section (1)
Groups
  1. Department of Medicine (57)
  2. Hematologic Malignancies, Division of (48)
  3. Center for Hematologic Malignancies (45)
  4. Lymphoma (42)
  5. Nursing (23)
  6. Population Sciences Research Program (21)

More Groups

People
  1. Andrew Zelenetz (39)
  2. Craig Moskowitz (35)
  3. David Straus (30)
  4. Carol Portlock (28)
  5. Paul Hamlin (23)
  6. Ariela Noy (22)

More People

Years
  1. 2010 (2)
  2. 2009 (2)
  3. 2008 (3)
  4. 2007 (8)
  5. 2006 (19)
  6. 2005 (17)

More Years

Publications
  1. Blood (30)
  2. Journal of Clinical Oncology (18)
  3. British Journal of Haematology (7)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (5)
  5. Clinical Cancer Research (4)
  6. Leukemia and Lymphoma (4)

More Publications

Publishers
  1. American Society of Hematology (30)
  2. American Society of Clinical Oncology (18)
  3. American Association for Cancer Research (11)
  4. John Wiley & Sons (7)
  5. Taylor & Francis Group (5)
  6. Springer (4)

More Publishers

Results (98)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I clinical trial of an oral histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W. K.; O'connor, O.; Richon, V. M.; Curley, T.; Richardson, S.; Thapi, D.; Chiao, J. H.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Emerging new targets and drugs for the treatment of lymphoma
    Journal Article

    O'Connor, O. A.
    Lymphoma Today (2003)

    Fulltext@MSK | Save
  • Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression
    Journal Article

    Wang, E. S.; O'connor, O.; She, Y.; Zelenetz, A. D.; Sirotnak, F. M.; Moore, M. A. S.
    Leukemia and Lymphoma (2003)

    Fulltext@MSK | Save
  • Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously
    Journal Article

    Kelly, Wm K.; Richon, V. M.; O'connor, O.; Curley, T.; Macgregor-Cortelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; more...
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Inhibition of VEGFR2 mediated paracrine pathways suppresses non-Hodgkin's lymphoma xenograft growth in NOD/SCID mice
    Meeting Abstract

    Wang, E. S.; Zhang, K.; O'connor, O.; Zhu, Z.; Hicklin, D.; Witte, L.; Zelenetz, A.; Rafii, S.; Moore, M. A. S.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • MAPAL cytocidal therapy for drug-resistant human breast cancer xenografts
    Meeting Abstract

    Martin, D. S.; Bertino, J.; Koutcher, J.; O'connor, O.; Alfieri, A.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)
    Meeting Abstract

    Kelly, W.; O'connor, O.; Richon, V. M.; Tong, W.; Rao, T. D.; Chiao, J.; O'Brien, J. P.; Rifkind, R. A.; Marks, P. A.; Scher, H. I.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase II clinical experience with the proteasome inhibitor PS-341 in patients with indolent lymphomas
    Meeting Abstract

    O'Connor, O. A.; Moskowitz, C. H.; Wright, J. J.; Macgregor-Cortelli, B.; Straus, D.; Furst, D.; Horse-Grant, D.; Schenkein, D. P.; Zelenetz, A. D.
    Blood (2002)

    Fulltext@MSK | Save
  • Transfer of drug resistance genes into marrow of NOD/SCID mice bearing a human lymphoma xenograft
    Meeting Abstract

    Budak-Alpdogan, T.; Alpdogan, O.; Banerjee, D.; O'Connor, O. A.; Moore, M. A. S.; Bertino, J. R.
    Blood (2002)

    Fulltext@MSK | Save
  • Clinical experience of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Richon, V.; Moskowitz, C. H.; Zelenetz, A. D.; Macgregor-Cortelli, B.; Curly, T.; Richardson, S.; Tong, W.; Rifkind, R.; Marks, P.; more...
    Blood (2002)

    Fulltext@MSK | Save